Clinical trials: Eradication Therapy of Helicobacter Pylori
HELICOBACTER PYLORI INFECTIONS
Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）
This study is designed to evaluate two different tegoprazan-based dual therapy regimens for the treatment of Helicobacter pylori (H. pylori) infection.
- Trial name
- FAST-HP (NCT07242443)
- Testing
- Tegoprazan 50 mg, Amoxicillin 1 g TID, Amoxicillin 1.5 g BID
- Where
- China
- Volunteers
- 240 people
- Sponsor
- First People's Hospital of Hangzhou
Helicobacter Pylori Infection, Dysbiosis
The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication
Helicobacter pylori (H. pylori) infection is the major cause of gastritis, peptic ulcer disease, and gastric cancer in adults. Bismuth-based quadruple therapy is recommended by a recent review to be the first-line treatment for…
- Conditions
- Helicobacter Pylori Infection, Dysbiosis, Probiotics
- Trial name
- Bsm10 (NCT04527055)
- Testing
- Bismuth Subcitrate 120 MG Oral Tablet, Lactobacillus acidophilus and Bifidobacterium lactis Bb12, Esomeprazole 40mg
- Where
- Taiwan
- Volunteers
- 312 people
- Sponsor
- National Cheng-Kung University Hospital
Helicobacter Pylori Infection
The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.
- Trial name
- NCT05173493
- Testing
- Amoxicillin,Furazolidone, Amoxicillin,Levofloxacin, Tetracycline,Furazolidone
- Where
- China
- Volunteers
- 670 people
- Sponsor
- Shandong University
Helicobacter Infection
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
As increasing the antibiotics resistance, the effectiveness of traditional Helicobacter pylori (H. pylori) therapies has been declined coincidently. In this study, the investigators evaluated the efficacy of H.
- Trial name
- NCT02349685
- Testing
- H. pylori culture and antimicrobial susceptibility test, 14 day PBMT group, 14 day MEA group
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection
Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori
This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori (H. pylori). A total of 162 patients with H.
- Trial name
- NCT03108287
- Testing
- RAK therapy, RBAK therapy
- Volunteers
- 162 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Helicobacter Pylori Infection, Chronic Gastritis
Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
The purpose of this study is to assess the efficacy and safety of berberine, amoxicillin and vonoprazan containing triple therapy in Helicobacter Pylori first-line eradication.
- Trial name
- NCT05014334
- Testing
- Berberine, Vonoprazan, Amoxicillin
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital of Digestive Diseases
Gastric Ulcer, Chronic Gastritis
Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
This study aims at evaluating efficacy and safety of berberine- amoxicillin containing quadruple therapy(berberine, amoxicillin, esomeprazole and bismuth) versus tetracycline-furazolidone quadruple therapy (tetracycline…
- Conditions
- Gastric Ulcer, Chronic Gastritis, Gastric Cancer, Helicobacter Pylori Infection
- Trial name
- NCT03609892
- Testing
- Berberine, Amoxicillin, Esomeprazole
- Where
- China
- Volunteers
- 658 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Helicobacter Pylori Infection
The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori
The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to antibiotics.
- Trial name
- NCT05189444
- Testing
- Vonoprazan, Amoxicillin, Esomeprazole
- Where
- China
- Volunteers
- 672 people
- Sponsor
- Huazhong University of Science and Technology
Helicobacter Pylori Infection
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication
Vonoprazan and high-dose amoxicillin dual therapy was used as a control group to evaluate the clinical efficiency and safety of Banxiaxiexin decoction combined with vonoprazan and high-dose amoxicillin dual therapy in the…
- Trial name
- NCT06340724
- Testing
- Vonoprazan, Amoxicillin, Banxiaxiexin decoction
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Helicobacter Pylori Infection
Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication
This study investigates the efficacy of a b.i.d. quadruple therapy containing Pylera® or L. reuteri for H. pylori infection.
- Trial name
- LactoBismu (NCT03925818)
- Testing
- Bismuth Subcitrate Potassium, Gastrus
- Where
- Italy
- Volunteers
- 99 people
- Sponsor
- Università degli Studi di Sassari
Helicobacter Pylori Infection
Comparison of the Effect of Helicobacter Pylori Eradication Before and After the Training of Gastroenterologists
The researchers recruited gastroenterologists. Physician subjects recruited Helicobacter pylori-positive patients before and after receiving standardized training on Helicobacter pylori eradication.
- Trial name
- NCT04984382
- Testing
- Standardized training on Helicobacter pylori eradication treatment
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Shandong University
Helicobacter Pylori Infection
Differences in the Eradication of Helicobacter Pylori by Different Therapies
To compare the performance of four treatment regimens for radical treatment of Helicobacter pylori, evaluating the efficacy, safety, patient compliance, and socioeconomic evaluation of the four regimens.
- Trial name
- NCT05097846
- Testing
- Group1 Vonoprazan Fumarate + amoxicillin + doxycycline, Group2 Vonoprazan Fumarate + furazolidone + doxycycline, Group3 esomeprazole + colloidal bismuth tartrate + amoxicillin + doxycycline
- Where
- China
- Volunteers
- 100 people
- Sponsor
- wang xiaoyan
Dyspepsia, Helicobacter-associated Gastritis
High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication
The purpose of this study is to compare the efficacy between 1-day high dose PPI-based triple therapy vs. 10-day sequential therapy for Helicobacter pylori eradication in functional dyspepsia patients.
- Conditions
- Dyspepsia, Helicobacter-associated Gastritis, Stomach Disorders
- Trial name
- NCT01888237
- Testing
- Double dose of PPI, sequence of drug use
- Where
- Thailand
- Volunteers
- 118 people
- Sponsor
- Mahidol University
Helicobacter Pylori Infection, Helicobacter Gastritis
Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication
The hypothesis and plan of the current study are: 1. One induction phase of high dose PPI before eradication will increase intragastric pH and induce H. pylori into an active replicative status.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Gastritis, Helicobacter-Associated Pyloric Ulcer
- Trial name
- NCT03802318
- Testing
- Rabeprazole
- Where
- Taiwan
- Volunteers
- 530 people
- Sponsor
- Chang Gung Memorial Hospital
HELICOBACTER PYLORI INFECTIONS
Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
With the increasing prevalence of antibiotic resistance, the clinical efficacy of conventional 7-day triple therapy for Helicobacter pylori eradication has been substantially diminished.
- Trial name
- PSM (NCT07333001)
- Testing
- 7-day triple therapy, 14-day dual therapy
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Yueyue Li
H. Pylori Infection
The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study
Helicobacter pylori infection has been shown to be associated with the development of gastric cancer and peptic ulcer diseases. Eradication of H. pylori infection could reduce the occurence or recurrence of these diseases.
- Trial name
- NCT00885417
- Testing
- Cravit-based sequential therapy
- Where
- Taiwan
- Volunteers
- 142 people
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
Tailored Vs. Empirical Helicobacter Pylori Infection Treatment
Helicobacter pylori (Hp) is a gram-negative bacterium that colonizes human gastric mucosa and is associated with chronic gastritis that can progress to severe complications such as peptic ulcer disease, gastric adenocarcinoma and…
- Trial name
- NCT06200779
- Testing
- Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
- Where
- Portugal
- Volunteers
- 160 people
- Sponsor
- Manuel Coelho da Rocha
HELICOBACTER PYLORI INFECTIONS
Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication
1. This study aims to compare the efficacy of empirical vonoprazan-based therapy versus susceptibility-guided vonoprazan-based therapy for third-line eradication of H. pylori. 2.
- Trial name
- NCT07130253
- Testing
- Vonoprazan based ET, Vonoprazan based SGT
- Where
- Taiwan
- Volunteers
- 220 people
- Sponsor
- National Taiwan University Hospital
Acute Coronary Syndrome
Relationship of Helicobacter Pylori Eradication Therapy and Long-term Outcome in Acute Coronary Syndrome
Objective: To investigate the relationship between Helicobacter pylori (Hp) infection and the prognosis of acute coronary syndrome (ACS) in a Chinese population and to explore the significance of Hp eradication therapy in…
- Trial name
- NCT02317445
- Volunteers
- 472 people
- Sponsor
- Capital Medical University
Helicobacter Pylori Infection, Sex
Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males
Helicobacter pylori eradication can reduce the risk of gastric cancer and decrease the recurrence of ulcers. However, in recent years, the increasing antibiotic resistance of Helicobacter pylori has reduced the efficacy of…
- Conditions
- Helicobacter Pylori Infection, Sex, Bismuth Quadruple Therapy
- Trial name
- NCT06509139
- Testing
- Drug: Bismuth Subcitrate 120 MG Oral Tablet, Esomeprazole 40mg, Metronidazole 250 MG
- Where
- Taiwan
- Volunteers
- 661 people
- Sponsor
- National Cheng-Kung University Hospital